Competitive Grants Program
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.
Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.
Sign Up for Alerts DetailsTitle Grant Type Focus Area Country Application Due Date Efforts to Improve Quality of Migraine CareRelease Date:Partner: The Japanese Headache SocietyQuality Improvement Internal Medicine Japan Improving Health Outcomes in Patients with ATTR-CM Through the Development of a Shared Decision-Making Tool (Decision Aid)Release Date:Research Rare Disease USA 2026 Hemophilia Fellowship – United StatesRelease Date:Fellowship Rare Disease All Improving Precision Oncology Care Through Molecular Diagnostic Integration and Data Quality ImprovementRelease Date:Quality Improvement Oncology Kazakhstan Implementing Germline and Somatic Testing for Precision Medicine in Community-Based Prostate Cancer CareEducation Oncology USA Improving Shared Decision Making in Hemophilia: Visiting Professorship ProgramRelease Date:Partner: Hemostasis & Thrombosis Research Society (HTRS)Education Rare Disease USA Improving Metastatic Prostate Cancer (mPCa) Care Through Innovative StrategiesRelease Date:Quality Improvement Oncology All Novel Therapies for Relapsed/Refractory Large B-Cell Lymphoma in Community Oncology PracticeRelease Date:Education Oncology USA Real-World Data Generation with Elranatamab in Relapsed/Refractory Multiple MyelomaRelease Date:Research Oncology China, France, Germany, Italy, Japan, Spain, Turkey, United Kingdom Pre-clinical Investigation of anti-TFPI-mediated Rebalancing Mechanisms in Non-Hemophilic Bleeding DisordersRelease Date:Research Rare Disease All Title Grant Type Focus Area Country Application Due Date Clinical Updates and Strategies in the Treatment and Management of First-line BRAF V600E-mutant Metastatic Colorectal CancerRelease Date:Education Oncology USA Guidelines and Best Practices in the Holistic Management of Patients with Metastatic Urothelial Carcinoma (mUC)Education Oncology USA Improving Atopic Dermatitis and Alopecia Areata Quality of Care to Standardize ManagementRelease Date:Partner: Beijing Guangda Precision Medicine Research CenterQuality Improvement Inflammation & Immunology China COVID-19 Disease Burden on the Pediatric PopulationRelease Date:Education Vaccines USA Post-COVID Conditions: Potential Diagnosis, Testing, Management, and Ongoing ResearchRelease Date:Education Vaccines USA Optimizing Antimicrobial Stewardship Program in Saudi ArabiaRelease Date:Quality Improvement Inflammation & Immunology Saudi Arabia Shared Decision Making in Hemophilia Patient CareRelease Date:Quality Improvement Rare Disease USA Real-World Data Generation with Elranatamab in Relapsed/Refractory Multiple MyelomaRelease Date:Research Oncology All Pharmacokinetics-pharmacodynamics (PK-PD) of aztreonam-avibactam (ATM-AVI) in Special PopulationsRelease Date:Research Inflammation & Immunology Austria, Denmark, Finland, Germany, Italy, Netherlands, Norway, Romania, Spain, Sweden, United Kingdom Invasive Mold Infections (IMI) - Real-World Evidence from Treatment Outcomes with IsavuconazoleRelease Date:Research Inflammation & Immunology Australia, Germany, Israel, Italy, Spain, Switzerland Optimizing maternal immunization practice in Malaysia Indonesia Singapore PhilippinesRelease Date:Quality Improvement Vaccines Indonesia, Malaysia, Philippines, Singapore PARP-Inhibitor Combination Treatments: Biomarker Testing, Safety, and Efficacy in a Rapidly Changing Metastatic Prostate CancerRelease Date:Education Oncology USA